On May 8, 2026, a federal jury returned the first-ever bellwether verdict in MDL 3081. If you received a Bard PowerPort during cancer treatment in Alabama or Tennessee, here is what that result actually means for your claim and why the litigation is far from over.
Our Bard PowerPort lawsuit attorneys at Cory Watson Attorneys have tracked every development in this MDL from the start.
The Current Status of MDL 3081 in 2026
All federal Bard PowerPort cases are consolidated in IN RE: Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081, before U.S. District Judge David G. Campbell in the District of Arizona. The MDL structure coordinates discovery and pretrial motions across all claims without eliminating individual plaintiffs' rights; each case remains separate and retains its own potential for damages.
As of May 2026, 3,187 lawsuits are pending in MDL 3081, over 1,000 filed in 2025 alone, more than doubling the 2024 count. Judge Campbell selected six bellwether cases across three injury categories: infections, thrombosis, and catheter fractures for jury trials running through February 2027.
Understanding the Result of the First Bellwether Trial
Cook v. Becton Dickinson went to trial on April 21, 2026. Plaintiff Robert Cook, a colorectal cancer patient, alleged his Bard PowerPort caused a severe infection at the Mayo Clinic requiring a six-day hospitalization, device removal, and a two-week delay in chemotherapy.
The jury returned a split verdict:
- Defense verdict on failure-to-warn. Jurors found that Bard did not fail to adequately warn patients or physicians about the risk of infection.
- Deadlock on design defects. The jury could not reach a unanimous decision on whether the PowerPort itself is defectively designed, the core allegation in the majority of the 3,000+ pending claims.
That deadlock matters. The design defect question is legally unresolved and fully open to future juries. Before trial, Judge Campbell had denied nearly all of Bard's motion for summary judgment, a significant plaintiff-side win that kept the design defect and failure-to-warn claims squarely before the jury.
Infection cases also carry an inherent evidentiary burden: defense counsel can attribute causation to patient health history, post-implantation handling, or hospital-acquired bacteria. The next round of bellwether trials will center on catheter fracture and thrombosis injuries, where the causal chain between device failure and physical harm is far more direct.
Upcoming Trial Dates and Settlement Negotiations
| Date | Bellwether Trial | Injury Focus |
| August 2026 | Trial 2 | Fracture / Thrombosis |
| October 2026 | Trial 3 | TBD |
| December 2026 | Trial 4 | TBD |
| February 2027 | Trials 5 & 6 | TBD |
The court has ordered both parties into formal settlement discussions in July 2026. No global resolution has been reached. MDL practitioners expect the August and October fracture-and-migration verdicts to be the primary lever in settlement valuation and those trials are weeks away.
Your case is not stalled on a single verdict; each new trial narrows the risk calculus for both sides.
Why Tennessee and Alabama Oncology Patients Are Impacted
Bard PowerPort devices are most often implanted in chemotherapy patients who require long-term IV access. Oncology centers across Birmingham, Huntsville, Memphis, and Nashville have implanted thousands of these devices.
The alleged defect is structural. The PowerPort's ChronoFlex AL catheter is composed of polyurethane and barium sulfate; barium sulfate was added to make the device visible on X-ray. Plaintiffs allege that Bard used excessive concentrations of barium sulfate, causing the polyurethane to weaken over time. A peer-reviewed study in the Journal of the Mechanical Behavior of Biomedical Materials (Braun et al., 2016, PMID: 27552159) found that barium sulfate particle loss creates "predetermined sites of fracture," microscopic structural failure points built into the catheter from the start.
Documented complications include:
- Catheter fragments migrating to the heart or pulmonary vessels
- Systemic infection and sepsis
- Thrombosis and pulmonary embolism
- Cardiac tamponade requiring emergency intervention
- Interrupted chemotherapy directly impacts cancer prognosis
Despite more than 400 FDA adverse event reports filed in just three months (December 2025 – February 2026), Bard has issued no recall covering the ChronoFlex catheter fracture. The device remains on the market with no updated warning labeling.
If you experienced a PowerPort infection, fracture, blood clot, or emergency procedure in Alabama or Tennessee, you may have a claim under our defective product litigation practice on theories of strict product liability, design defect, manufacturing defect, and failure to warn.
How to Join the Consolidated Litigation
Your case files are in MDL 3081 individually. Pretrial work is handled collectively; your facts, damages, and right to compensation remain entirely your own.
Basic eligibility requires:
- Confirmed implantation of a Bard PowerPort, BardPort, SlimPort, or X-Port with a ChronoFlex catheter
- A documented related injury: infection, fracture, migration, thrombosis, or surgical removal
- Medical records connecting device use to your diagnosis or treatment
Statute of limitations: Most states permit 2 to 4 years from the date of injury or the date you discovered that the device caused your harm. That clock is running. Contact us today before that window closes.
Representation is on a contingency-fee basis. You pay nothing unless we recover on your behalf.
To learn more about us and our record in mass-tort and defective-device litigation, or to submit your case directly, visit our Bard PowerPort lawsuit page.
About Cory Watson Attorneys: Cory Watson Attorneys is a Birmingham-based mass tort firm with 44+ years of experience and more than $4 billion recovered for injured clients. Offices in Birmingham, Memphis, and Nashville. Actively accepting Bard PowerPort claims in MDL 3081. Available 24/7 at (877) 562-0000.